Psoriatic Arthritis

November 24, 2020

More than half of patients with psoriatic arthritis have to wait two or more years for a diagnosis, researchers report.

November 24, 2020

Many patients with psoriatic arthritis live with unacceptable levels of disease activity despite treatment, and patient-reported outcomes could provide useful treatment targets, shows a new study.

November 10, 2020

In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.

November 06, 2020

In a study that examined the effects of guselkumab (Tremfya, Janssen) on fatigue in patients with psoriatic arthritis, the treatment reduced fatigue through one year, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

September 30, 2020

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

September 25, 2020

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

September 11, 2020

The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.

September 10, 2020

Treat-to-target strategies can be effective in addressing rheumatic diseases like psoriatic arthritis, but may not be enough on their own to single-handedly improve quality of life for those living with the disease, write physicians in a new article in Arthritis and Rheumatology.